We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study.
- Authors
Hilfiker-Kleiner, Denise; Haghikia, Arash; Berliner, Dominik; Vogel-Claussen, Jens; Schwab, Johannes; Franke, Annegret; Schwarzkopf, Marziel; Ehlermann, Philipp; Pfister, Roman; Michels, Guido; Westenfeld, Ralf; Stangl, Verena; Kindermann, Ingrid; Kühl, Uwe; Angermann, Christiane E.; Schlitt, Axel; Fischer, Dieter; Podewski, Edith; Böhm, Michael; Sliwa, Karen
- Abstract
Aims An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM. Methods and results In this multicentre trial, 63 PPCM patients with left ventricular ejection fraction (LVEF) ≤35% were randomly assigned to short-term (1W: bromocriptine, 2.5 mg, 7 days) or long-term bromocriptine treatment (8W: 5 mg for 2 weeks followed by 2.5 mg for 6 weeks) in addition to standard heart failure therapy. Primary end point was LVEF change (delta) from baseline to 6 months assessed bymagnetic resonance imaging. Bromocriptinewas well tolerated. Left ventricular ejection fraction increased from 28± 10% to 49 ± 12% with a delta-LVEF of + 21 ± 11% in the 1W-group, and from 27 ± 10% to 51 ± 10% with a delta-LVEF of + 24 ± 11% in the 8W-group (delta-LVEF: P = 0.381). Full-recovery (LVEF ≥ 50%) was present in 52% of the 1W-and in 68% of the 8W-group with no differences in secondary end points between both groups (hospitalizations for heart failure: 1W: 9.7% vs. 8W: 6.5%, P = 0.651). The risk within the 8W-group to fail full-recovery after 6 months tended to be lower. No patient in the study needed heart transplantation, LV assist device or died. Conclusion Bromocriptine treatment was associated with high rate of full LV-recovery and low morbidity and mortality in PPCM patients compared with other PPCM cohorts not treated with bromocriptine. No significant differences were observed between 1W and 8W treatment suggesting that 1-week addition of bromocriptine to standard heart failure treatment is already beneficial with a trend for better full-recovery in the 8W group.
- Publication
European Heart Journal, 2017, Vol 38, Issue 35, p2671
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehx355